---
title: "Kodiak Sciences Inc. (KOD.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/KOD.US.md"
symbol: "KOD.US"
name: "Kodiak Sciences Inc."
industry: "Biotechnology"
datetime: "2026-05-20T17:04:40.108Z"
locales:
  - [en](https://longbridge.com/en/quote/KOD.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KOD.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KOD.US.md)
---

# Kodiak Sciences Inc. (KOD.US)

## Company Overview

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company’s preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [kodiak.com](https://kodiak.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -9.23 | 443 | - | - | - |
| PB | 18.99 | 413 | 62.13 | 15.76 | 3.82 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-12T04:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 86% |
| Overweight | 1 | 14% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 36.17 |
| Highest Target | 80.00 |
| Lowest Target | 14.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/KOD.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/KOD.US/norm.md)
- [Related News](https://longbridge.com/en/quote/KOD.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/KOD.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**